Recent news on

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of ...  -  25 May 2007
openPR (press release),...(openPR) - The chemotherapy drug docetaxel currently offers the best treatment for androgen-independent prostate cancer. That is the result of a now

AUA 2007 - Systemic Therapy of Advanced Prostate Cancer II  -  25 May 2007
UroToday,The impact of the PSA flare with docetaxel therapy was evaluated by Nelius and associates [ ABST 1010]. Eight patients from a treatment cohort of 74 were

AUA 2007 - Plenary Session: State-of-the-Art "Novel Treatment ...  -  25 May 2007
UroToday,In a study performed at Columbia University, intravesical docetaxel for BCG failures demonstrated a 33% CR rate at 14 months. He said that non-vesicant

Zenotech sues DAE, Tata hospital on drug supply row  -  25 May 2007
Financial Express,...in India and yet it has not been considered. In the case of docetaxel, the awardee does not have a manufacturing facility for the drug,� he added.

AUA 2007 - Plenary Session: Point-Counterpoint; "Managing High ...  -  25 May 2007
UroToday,Dr. Glode stated that clinical trial consideration should come first, and present trials look at use of docetaxel as adjuvant therapy in higher risk

Oral and IV Hycamtin® Equally Effective for Small Cell Lung Cancer  -  25 May 2007
Cancer Consultants (press release),Docetaxel is a commonly used chemotherapy agent for the palliative treatment of recurrent NSCLC. However, Taxotere is administered intravenously,

Dendreon's New Double-Twist  -  May 21, 2007
24/7 Wall St.,The abstract, "Advanced Prostate Cancer Patients who Receive Sipuleucel-T followed by Docetaxel Have Prolonged Survival," was authored by Daniel P. Petrylak

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus ...  -  Apr 25, 2007
Cancer Focus,..."This data reaffirms the potential of bavituximab for the treatment of prostate cancer in combination with docetaxel and is particularly timely since we

Lung Cancer is the Third Most Common Malignant Disease and the ...  -  May 13, 2007
Fuerteventura Digital,These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options.

Additional Efficacy Data from Satraplatin SPARC Phase 3 ...  -  May 21, 2007
PR Newswire (press release),These results were consistent across multiple pre-defined subsets of patients, including patients treated with prior Taxotere(R) (docetaxel).

Provenge Followed by Taxotere May Improve Survival in Metastatic ...  -  May 23, 2007
Cancer Consultants (press release),...with asymptomatic metastatic androgen independent prostate cancer (AIPC) who received the vaccine followed by Taxotere® (docetaxel) at progression.

Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial ...  -  May 21, 2007
PR Newswire (press release),These results were consistent across subsets, including patients treated with prior Taxotere(R) (docetaxel). All pain progression events were adjudicated by

Cytogen Reports First Quarter 2007 Financial Results  -  May 10, 2007
PharmaLive.com (press release),This includes the initiation of a Phase 2 study evaluating QUADRAMET and docetaxel for the treatment of hormone-refractory prostate cancer and a Phase 2

The first combination of targeted therapies for any cancer to ...  -  May 3, 2007
PipelineReview.com (press release),Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer.

Neoadjuvant Taxotere®, Navelbine®, and Herceptin® Active for ...  -  May 3, 2007
Cancer Consultants (press release),Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human

INNOVIVE Pharmaceuticals: Wall Street Analyst Forum Presentation ...  -  May 22, 2007
Seeking Alpha,If they get Gemcitabine $1.5 billion, going off patent in the next three years, Docetaxel over $2 billion, going off patent in the next three years.

Cytokinetics Announces Clinical Trials Data to Be Presented at the ...  -  May 18, 2007
Genetic Engineering News (press release),...anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel.

Deadly Cancers Dealt A Knockout Punch  -  May 14, 2007
Medical News Today (press release),...authorities to test Reolysin in three separate human trials in combination with the cancer drugs gemcitabine, paclitaxel/carboplatin and docetaxel.

Cancer sufferers to be denied drug on NHS  -  May 14, 2007
Daily Mail,..."There is now a postcode lottery as the Scottish Medicines Consortium (SMC) has approved not only cetuximab but also docetaxel (another head and neck cancer

NHS cancer patients are denied new drug  -  May 13, 2007
Telegraph.co.uk,..."There is now a postcode lottery as the Scottish Medicines Consortium has approved not only cetuximab but also docetaxel [another head and neck cancer drug]

Cell Genesys Reports First Quarter 2007 Results  -  May 10, 2007
PR Newswire (press release),...survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel) chemotherapy plus prednisone,

ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic ...  -  26 Apr 2007
PipelineReview.com (press release),The study results indicate bioequivalent pharmacokinetics between ANX-514 and the FDA-approved version of docetaxel, marketed under the brand name

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus ...  -  26 Apr 2007
Cancer Focus,..."This data reaffirms the potential of bavituximab for the treatment of prostate cancer in combination with docetaxel and is particularly timely since we

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus ...  -  Apr 17, 2007
PR Newswire (press release),Combination Therapy Significantly Decreased Tumor Blood Vessel Density and Serum PSA Levels in Prostate Tumors - - Docetaxel One of Chemotherapies Being

ADVENTRX Grants Manufacturing Contract for ANX-514 (Docetaxel ...  -  Apr 5, 2007
PR Newswire (press release),About ANX-514 (docetaxel emulsion) ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a product marketed under the brand name

ADVENTRX Grants Manufacturing Contract for ANX-514 (Docetaxel ...  -  Apr 5, 2007
PharmaLive.com (press release),ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a product marketed under the brand name Taxotere.

Adventrx Grants Manufacturing Contract for Novel Docetaxel ...  -  Apr 5, 2007
Genetic Engineering News (press release),Adventrx Pharmaceuticals entered into an agreement with Hyaluron Contract Manufacturing related to ANX-514 (docetaxel emulsion). It is a novel nano-emulsion

OncoGenex Technologies Announces Phase II Data of OGX-011 in ...  -  Apr 18, 2007
PipelineReview.com (press release),OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with metastatic breast

OncoGenex Technologies Announces Phase II Data of OGX-011 in ...  -  Apr 17, 2007
PR Newswire (press release),VANCOUVER, April 17 /PRNewswire/ - OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel

Lorus Therapeutics Announces Scientific Presentations for Lead ...  -  Apr 17, 2007
PipelineReview.com (press release),The first presentation titled, "Determination of optimized administration schedule of GTI-2040 and docetaxel combination treatment for NSCLC cells in vitro

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist ...  -  Apr 17, 2007
CNW Telbec (Communiqués de presse),Results The poster #3568 "GHRH-Antagonist in Combination with Docetaxel Chemotherapy induces regression of MX-1 human experimental breast cancers," reviewed

OncoGenex Technologies Announces Phase II Data of OGX-011 in ...  -  Apr 17, 2007
PharmaLive.com (press release),..."We are encouraged by the conclusion made by the investigators that the combination of OGX-011 and docetaxel has activity in this patient population and by

Taxane Use And Dose-Dense Scheduling May Benefit Patients With ...  -  Apr 14, 2007
Medical News Today (press release),Cytokine support is often required to reduce toxicity with dose-dense therapy, or with higher-dose docetaxel regimens. The Committee considered multiple

terna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR ...  -  Apr 17, 2007
PipelineReview.com (press release),The poster #3568 "GHRH-Antagonist in Combination with Docetaxel Chemotherapy induces regression of MX-1 human experimental breast cancers," reviewed

Clarifying the Issues Surrounding Dendreon's Provenge  -  Apr 16, 2007
Seeking Alpha,In the Columbia Presbyterian Phase II trial of docetaxel and estramustine, the occurrence of vascular events, including grade 4 and 5 cerebrovascular

Contract manufacturing news in brief  -  Apr 16, 2007
In-PharmaTechnologist.com,The compound is being groomed as a "follow-on" or "biosimilar" competitor for the branded chemotherapy drug Taxotere (docetaxel), which is approved to treat

Lorus Therapeutics Announces Scientific Presentations For ...  -  Apr 17, 2007
Trading Markets,The first presentation titled, determination of optimized administration schedule of GTI-2040 and docetaxel combination treatment for NSCLC cells in vitro

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist ...  -  Apr 17, 2007
PR-Inside.com (Pressemitteilung),Docetaxel at a single dose of 20 mg/kg ip significantly reduced tumor volume and weight by 74.1% and 58.6 %, respectively.

Bioxel Pharma: Results for Fiscal 2006  -  Mar 29, 2007
CCNMatthews (press release),..."We pursued our new taxane development program, thereby moving closer to the commercial scale-up of docetaxel and semi-synthetic paclitaxel.

OncoGenex Reports Response Data from OCX-011 Phase II  -  Apr 17, 2007
Therapeutics Daily (subscription) (press release),OncoGenex Technologies Inc. said encouraging data were reported from a Phase II trial of OGX-011 in combination with docetaxel in patients with metastatic

The Association Between Measures Of Progression And Survival In ...  -  Apr 23, 2007
Medical News Today (press release),The study included; 40 men treated with docetaxel/estramustine/carboplatin, 24 patients treated with docetaxel/intravenous estramustine and carboplatin,

Viventia Biotech announces results of Proxinium antibody in ...  -  Apr 22, 2007
News-Medical.net,The combination of Proxinium with cisplatin, carboplatin, paclitaxel, 5-fluorouracil, and docetaxel resulted in a significant additive cytotoxic effect (p

Cell Genesys shares soar over promising cancer immunotherapy data  -  Apr 4, 2007
Pharma Times (subscription),Cell Genesys noted that GVAX immunotherapy is currently being studied as a single agent and in combination with docetaxel chemotherapy in two Phase III

Cell Genesys Up Sharply on Clinical Trial Results  -  Apr 3, 2007
International Business Times,The GVAX immunotherapy is currently being tested alone and in combination with docetaxel chemotherapy in two Phase III clinical trials.

Avastin approved in Europe for first line treatment of women with  -  Apr 2, 2007
WebWire (press release),Additional phase III trials are ongoing to explore Avastin in the first line treatment of metastatic breast cancer in combination with docetaxel (AVADO) and

Sequential Chemotherapy Helpful in Advanced Lung Cancer  -  Mar 29, 2007
Cancerpage.com,In this context, she added, "the sequential regimen evaluated in our paper, with cisplatin and gemcitabine followed by weekly docetaxel as first-line

Avastin approved for metastatic breast cancer in EU  -  Mar 29, 2007
Pharma Times (subscription),Recently, a Phase III first-line trial was initiated, called AVEREL, into HER2-positive breast cancer evaluating Avastin in combination with docetaxel plus

Peregrine Pharmaceuticals Highlights Significant Advances In The ...  -  Apr 21, 2007
Medical News Today (press release),A bavituximab equivalent in combination with the common cancer chemotherapy docetaxel reduced the growth of both hormone-dependent and hormone-independent

Cell Genesys says prostate cancer drug trial shows promise  -  Apr 3, 2007
Therapeutics Daily (subscription) (press release),The company is currently studying GVAX immunotherapy as a single agent and in combination with docetaxel chemotherapy in two late-stage clinical trials.

FDA panel OKs new prostate cancer vaccine  -  Mar 29, 2007
Long Beach Press-Telegram,...compared to those given only dummy treatment. The only other prostate cancer drug shown to prolong the lives of patients is Taxotere, also called docetaxel.

Abraxis BioScience Presents Pre-Clinical Findings That Support ...  -  Apr 19, 2007
PharmaLive.com (press release),Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR

Micromet Achieves Milestone in BiTE(R) Research Collaboration with ...  -  Apr 23, 2007
PipelineReview.com (press release),In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic

Viventia biotech reports synergistic effect of its Proxinium(TM ...  -  Apr 18, 2007
CNW Telbec (Communiqués de presse),The combination of Proxinium(TM) with cisplatin, carboplatin, paclitaxel, 5-fluorouracil, and docetaxel resulted in a significant additive cytotoxic effect

Cell Genesys reports data from clinical trials of GVAX ...  -  Apr 18, 2007
News-Medical.net,GVAX immunotherapy for prostate cancer is currently being studied both as a single agent and in combination with docetaxel chemotherapy in two Phase 3

Cougar Biotechnology Presents Positive CB7630 Clinical Data at ...  -  Apr 18, 2007
PipelineReview.com (press release),Of the 19 patients who have been treated, CB7630 was well tolerated with only minimal toxicity in this post-docetaxel population.

American Society of Breast Disease Affirms Use of Taxanes, Dose ...  -  Apr 18, 2007
DG NewsThe second states that while taxanes offer an advantage over non-taxane-containing regimens, the optimal taxane (paclitaxel vs docetaxel) has yet to be

Micromet Achieves Milestone in BiTE(R) Research Collaboration with ...  -  Apr 23, 2007
PR-Inside.com (Pressemitteilung),In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic

AEterna Zentaris To Present First In Vitro Data for PI3K ...  -  Apr 13, 2007
PR-Inside.com (Pressemitteilung),Tuesday, April 17, 8:00 am - 12:00 pm (PT) - Abstract #3568 "GHRH-Antagonist in Combination with Docetaxel Chemotherapy induces regression of MX-1 human

Cell Genesys Provides Final Median Survival Data From Second Phase ...  -  Apr 5, 2007
Drug Newswire (press release),GVAX immunotherapy for prostate cancer is currently being studied as a single agent and in combination with docetaxel chemotherapy in two Phase 3 clinical

Neoadjuvant Taxotere®, Navelbine® and Herceptin® Active for ...  -  Apr 4, 2007
Cancer Consultants (press release),Researchers involved in a multicenter trial have reported that a regimen of Taxotere (docetaxel), Navelbine (venorelbine) and Herceptin® produces a 39%

FDA advisers OK prostate cancer vaccine  -  Mar 29, 2007
Herald News Daily,The only other prostate cancer drug shown to prolong the lives of patients is Taxotere, also called docetaxel. If ultimately approved, Provenge would become

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional